MiRNAs as biomarkers of myocardial infarction: A step forward towards personalized medicine?

Trends in Molecular Medicine

Volumn 20, Issue 12, 2014, Pages 716-725

  Goretti, Emeline ^a   Wagner, Daniel R ^a,b   Devaux, Yvan ^a  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^b CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

Author keywords

Biomarker; MiRNAs; Myocardial infarction; Personalized medicine; Therapeutic targets

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; MICRORNA; MICRORNA 1; MICRORNA 133A; MICRORNA 208; MICRORNA 499; UNCLASSIFIED DRUG; GENETIC MARKER; TROPONIN;

ACUTE HEART INFARCTION; ASSAY; AUTOMATION; BIOSENSOR; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMOLUMINESCENCE; CLINICAL ASSESSMENT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; GENE EXPRESSION REGULATION; GENOME; HEART INFARCTION; HUMAN; LABORATORY TEST; MEASUREMENT; PERSONALIZED MEDICINE; PROGNOSIS; RELIABILITY; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SENSOR; TRANSCRIPTION REGULATION; ANIMAL; BLOOD; DISEASE MODEL; GENETIC MARKER; GENETICS; METABOLISM; MYOCARDIAL INFARCTION; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENETIC MARKERS; HUMANS; INDIVIDUALIZED MEDICINE; MICRORNAS; MYOCARDIAL INFARCTION; PROGNOSIS; TREATMENT OUTCOME; TROPONIN;

EID: 84915754365     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2014.10.006     Document Type: Review

References (93)

1. Gonzalez de Castro D., et al. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin. Pharmacol. Ther. 2013, 93:252-259.
2. Thygesen K., et al. Third universal definition of myocardial infarction. Eur. Heart J. 2012, 33:2551-2567.
3. Jaffe A.S., et al. Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T. J. Am. Coll. Cardiol. 2011, 58:1819-1824.
4. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
5. Orom U.A., et al. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol. Cell 2008, 30:460-471.
6. Tay Y., et al. MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature 2008, 455:1124-1128.
7. Bauersachs J., Thum T. Biogenesis and regulation of cardiovascular microRNAs. Circ. Res. 2011, 109:334-347.
8. Hata A. Functions of microRNAs in cardiovascular biology and disease. Annu. Rev. Physiol. 2013, 75:69-93.
9. Wystub K., et al. miR-1/133a clusters cooperatively specify the cardiomyogenic lineage by adjustment of myocardin levels during embryonic heart development. PLoS Genet. 2013, 9:e1003793.
10. Karakikes I., et al. Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J. Am. Heart Assoc. 2013, 2:e000078.
11. Friedman R.C., et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009, 19:92-105.
12. Mitchell P.S., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:10513-10518.
13. Boon R.A., Vickers K.C. Intercellular transport of microRNAs. Arterioscler. Thromb. Vasc. Biol. 2013, 33:186-192.
14. Kumarswamy R., Thum T. Non-coding RNAs in cardiac remodeling and heart failure. Circ. Res. 2013, 113:676-689.
15. Montecalvo A., et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. Blood 2012, 119:756-766.
16. Akao Y., et al. Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages. Mol. Ther. 2011, 19:395-399.
17. Zernecke A., et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci. Signal. 2009, 2:ra81.
18. Arroyo J.D., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:5003-5008.
19. Vickers K.C., et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011, 13:423-433.
20. Granger C.B., et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch. Intern. Med. 2003, 163:2345-2353.
21. Wilson P.W., et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
22. Zampetaki A., et al. Prospective study on circulating microRNAs and risk of myocardial infarction. J. Am. Coll. Cardiol. 2012, 60:290-299.
23. Wang S., et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell 2008, 15:261-271.
24. Willeit P., et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ. Res. 2013, 112:595-600.
25. Taibi F., et al. miR-223: an inflammatory oncomiR enters the cardiovascular field. Biochim. Biophys. Acta 2014, 1842:1001-1009.
26. Gilad S., et al. Serum microRNAs are promising novel biomarkers. PLoS ONE 2008, 3:e3148.
27. De Rosa S., et al. Transcoronary concentration gradients of circulating microRNAs. Circulation 2011, 124:1936-1944.
28. Akat K.M., et al. Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:11151-11156.
29. Roy S., et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc. Res. 2009, 82:21-29.
30. Shi B., et al. Altered expression of microRNAs in the myocardium of rats with acute myocardial infarction. BMC Cardiovasc. Disord. 2010, 10:11.
31. Kuwabara Y., et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ. Cardiovasc. Genet. 2011, 4:446-454.
32. Wang G.K., et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur. Heart J. 2010, 31:659-666.
33. Liebetrau C., et al. Release kinetics of circulating muscle-enriched microRNAs in patients undergoing transcoronary ablation of septal hypertrophy. J. Am. Coll. Cardiol. 2013, 62:992-998.
34. D'Alessandra Y., et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur. Heart J. 2010, 31:2765-2773.
35. Ai J., et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem. Biophys. Res. Commun. 2010, 391:73-77.
36. Cheng Y., et al. A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. Clin. Sci. (Lond.) 2010, 119:87-95.
37. Corsten M.F., et al. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ. Cardiovasc. Genet. 2010, 3:499-506.
38. Adachi T., et al. Plasma microRNA 499 as a biomarker of acute myocardial infarction. Clin. Chem. 2010, 56:1183-1185.
39. Widera C., et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J. Mol. Cell. Cardiol. 2011, 51:872-875.
40. Devaux Y., et al. Use of circulating microRNAs to diagnose acute myocardial infarction. Clin. Chem. 2012, 58:559-567.
41. Gidlof O., et al. Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction. BMC Cardiovasc. Disord. 2013, 13:12.
42. Devaux Y., et al. Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain. J. Int. Med. 2013, Published online December 17, 2013, http://dx.doi.org/10.1111/joim.12183.
43. Wang R., et al. Circulating microRNAs are promising novel biomarkers of acute myocardial infarction. Intern. Med. 2011, 50:1789-1795.
44. Gidlof O., et al. Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples. Cardiology 2011, 118:217-226.
45. Olivieri F., et al. Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction. Int. J. Cardiol. 2013, 167:531-536.
46. Zeller T., et al. Assessment of microRNAs in patients with unstable angina pectoris. Eur. Heart J. 2014, 35:2106-2114.
47. Fichtlscherer S., et al. Circulating microRNAs in patients with coronary artery disease. Circ. Res. 2010, 107:677-684.
48. Li Y.Q., et al. Comparing the diagnostic values of circulating microRNAs and cardiac troponin T in patients with acute myocardial infarction. Clinics 2013, 68:75-80.
49. Tijsen A.J., et al. Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases. Am. J. Physiol. Heart Circ. Physiol. 2012, 303:H1085-H1095.
50. Creemers E.E., et al. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?. Circ. Res. 2012, 110:483-495.
51. Oerlemans M.I., et al. Early assessment of acute coronary syndromes in the emergency department: the potential diagnostic value of circulating microRNAs. EMBO Mol. Med. 2012, 4:1176-1185.
52. Talwar S., et al. Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur. Heart J. 2000, 21:1514-1521.
53. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) et al. (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 33, 2569-2619.
54. Eitel I., et al. Relation of circulating microRNA-133a concentrations with myocardial damage and clinical prognosis in ST-elevation myocardial infarction. Am. Heart J. 2012, 164:706-714.
55. Goretti E., et al. Association between circulating microRNAs, cardiovascular risk factors and outcome in patients with acute myocardial infarction. Int. J. Cardiol. 2013, 168:4548-4550.
56. Olivieri F., et al. Admission levels of circulating miR-499-5p and risk of death in elderly patients after acute non-ST elevation myocardial infarction. Int. J. Cardiol. 2014, 172:e276-e278.
57. Matsumoto S., et al. A subset of circulating microRNAs are predictive for cardiac death after discharge for acute myocardial infarction. Biochem. Biophys. Res. Commun. 2012, 427:280-284.
58. Zile M.R., et al. Relationship between the temporal profile of plasma microRNA and left ventricular remodeling in patients following myocardial infarction. Circ. Cardiovasc. Genet. 2011, 4:614-619.
59. Matsumoto S., et al. Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circ. Res. 2013, 113:322-326.
60. Devaux Y., et al. MicroRNA-150: a novel marker of left ventricular remodeling after acute myocardial infarction. Circ. Cardiovasc. Genet. 2013, 6:290-298.
61. Devaux Y., et al. A panel of 4 microRNAs facilitates the prediction of left ventricular contractility after acute myocardial infarction. PLoS ONE 2013, 8:e70644.
62. Meder B., et al. MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res. Cardiol. 2011, 106:13-23.
63. Wu C., et al. The human MTHFR rs4846049 polymorphism increases coronary heart disease risk through modifying miRNA binding. Nutr. Metab. Cardiovasc. Dis. 2013, 23:693-698.
64. Clop A., et al. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat. Genet. 2006, 38:813-818.
65. Sethupathy P., et al. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3' untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am. J. Hum. Genet. 2007, 81:405-413.
66. Zhou B., et al. Common genetic polymorphisms in pre-microRNAs were associated with increased risk of dilated cardiomyopathy. Clin. Chim. Acta 2010, 411:1287-1290.
67. Zhi H., et al. Polymorphisms of miRNAs genes are associated with the risk and prognosis of coronary artery disease. Clin. Res. Cardiol. 2012, 101:289-296.
68. Mencia A., et al. Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss. Nat. Genet. 2009, 41:609-613.
69. Dorn G.W., et al. A human 3' miR-499 mutation alters cardiac mRNA targeting and function. Circ. Res. 2012, 110:958-967.
70. de Boer H.C., et al. Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. Eur. Heart J. 2013, 34:3451-3457.
71. Kaudewitz D., et al. Impact of intravenous heparin on quantification of circulating microRNAs in patients with coronary artery disease. Thromb. Haemost. 2013, 110:609-615.
72. Koshiol J., et al. Strengths and limitations of laboratory procedures for microRNA detection. Cancer Epidemiol. Biomark Prev. 2010, 19:907-911.
73. Sato F., et al. Intra-platform repeatability and inter-platform comparability of microRNA microarray technology. PLoS ONE 2009, 4:e5540.
74. Dong H., et al. Trace and label-free microRNA detection using oligonucleotide encapsulated silver nanoclusters as probes. Anal. Chem. 2012, 84:8670-8674.
75. Johnson B.N., Mutharasan R. Sample preparation-free, real-time detection of microRNA in human serum using piezoelectric cantilever biosensors at attomole level. Anal. Chem. 2012, 84:10426-10436.
76. Fang S., et al. Attomole microarray detection of microRNAs by nanoparticle-amplified SPR imaging measurements of surface polyadenylation reactions. J. Am. Chem. Soc. 2006, 128:14044-14046.
77. Johnson B.N., Mutharasan R. Biosensor-based microRNA detection: techniques, design, performance, and challenges. Analyst 2014, 139:1576-1588.
78. Roy S., et al. A microfluidic-assisted microarray for ultrasensitive detection of miRNA under an optical microscope. Lab Chip 2011, 11:1886-1894.
79. Gladka M.M., et al. Small changes can make a big difference - microRNA regulation of cardiac hypertrophy. J. Mol. Cell. Cardiol. 2012, 52:74-82.
80. Wang J.X., et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat. Med. 2011, 17:71-78.
81. Banzet S., et al. Changes in circulating microRNAs levels with exercise modality. J. Appl. Physiol. (1985) 2013, 115:1237-1244.
82. Baggish A.L., et al. Dynamic regulation of circulating microRNA during acute exhaustive exercise and sustained aerobic exercise training. J. Physiol. 2011, 589:3983-3994.
83. Li S., et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation 2011, 124:175-184.
84. Zampetaki A., et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ. Res. 2010, 107:810-817.
85. Sun X., et al. Circulating microRNA-126 in patients with coronary artery disease: correlation with LDL cholesterol. Thromb. J. 2012, 10:16.
86. Fukushima Y., et al. Assessment of plasma miRNAs in congestive heart failure. Circ. J. 2011, 75:336-340.
87. Bye A., et al. Circulating microRNAs and aerobic fitness - the HUNT Study. PLoS ONE 2013, 8:e57496.
88. Kong L., et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol. 2011, 48:61-69.
89. Karolina D.S., et al. Circulating miRNA profiles in patients with metabolic syndrome. J. Clin. Endocrinol. Metab. 2012, 97:E2271-E2276.
90. Gao W., et al. Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis. 2012, 11:55.
91. Caporali A., et al. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 2011, 123:282-291.
92. Duttagupta R., et al. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS ONE 2011, 6:e20769.
93. Takahashi K., et al. Cigarette smoking substantially alters plasma microRNA profiles in healthy subjects. Toxicol. Appl. Pharmacol. 2013, 272:154-160.